GenomeFrontier Therapeutics TW Co., Ltd.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and
Founded Year
2018
Unified Business No.
50792421
Status
Active
Number of Employees
0
Total Paid-in
Capital
744,706,939 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
GenomeFrontier Therapeutics, Inc. is an innovation-driven gene therapy company based in Taiwan, focused on developing next‑generation virus-free gene and cell therapies. Leveraging four proprietary cell engineering platforms, they have built their core Quantum Engine™ system to enable safer, more effective treatments for cancer and other challenging diseases.
